Mirapex (pramipexole): Drug Safety Communication – Ongoing Safety Review, Possible Risk of Heart Failure

by FDA on September 19, 2012

in MedWatch

FDA currently evaluating analysis of randomized clinical trials and epidemiologic studies.

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Leave a Comment

Previous post:

Next post: